Managed care cost-containment strategies and their impact on physician prescribing and treatment of depression. Based on a presentation by Robert K. Schreter, MD.
Pharmacy costs are outpacing other healthcare expenditures, with psychotropic medications accounting for 16% to 25% of the total pharmacy costs. Managed care organizations (MCOs) can be expected to exert considerable pressure to control such costs. Avenues for cost containment include changing the management and spending decisions of MCOs, influencing physician prescribing patterns, encouraging economically efficient pharmacy policies and procedures, and controlling patient access to prescription drugs. From the cost standpoint of an MCO, briefer approaches to treating depressed patients are desirable. The MCOs prefer a limited number of psychotherapeutic sessions, rapid titration and prescription of higher dosage levels of appropriate drugs, and a longer continuation phase of pharmacological treatment to avert a relapse.
D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use*; D003363:Cost Control; D003863:Depression / Q000188:drug therapy*; D011307:Drug Prescriptions; D005569:Formularies as Topic; D006801:Humans; D008329:Managed Care Programs / Q000191:economics*; D010818:Practice Patterns, Physicians'
D000928:Antidepressive Agents